Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer: an Open-label, Non-comparative, Phase 1b/2 Dose Escalation and Expansion Trial

NCT06776757 is registered in ClinicalTrials.gov with Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center as lead sponsor.

NCT NCT06776757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06776757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer: an Open-label, Non-comparative, Phase 1b/2 Dose Escalation and Expansion Trial
Lead sponsor
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 25, 2023
Completion date
December 25, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer